HOTLINE 24/7/365 UK: +44 (0) 1483 212150

Training

saphar_page_logoSaPhar Ltd, our sister company, provides a comprehensive Pharmacovigilance training programme globally for both our clients and PharSafer® personnel. Established in 2002, SaPhar has conducted Pharmacovigilance training at all levels including; introductory, intermediate and advanced around the world.

SaPhar is totally flexible in its approach to the vital aspects of Pharmacovigilance training, offering interactive and understandable modules. We are able to train staff internally or externally on essential safety reporting, from receptionists to sales representatives, customer services, medical information and PV Associates, to ensure that all Company personnel know how to report any adverse events that they may receive.

We also perform competency testing to ensure that all staff have understood the elements of the training course. PharSafer® also works with other training companies in the support of Pharmacovigilance training and has conducted training on-site and off-site, via webinars and using interactive e-learning programmes.

Our training programmes are carefully designed to allow the attendee to progress their knowledge over time by attending more varied and complex courses.

Typical attendees at our training courses have been: Clinical; Pharmacovigilance; Regulatory; IT; QA; Medical Information; Medical Directors, other CROs and even CEOs.

Feedback from our courses has also been important to us and some courses (modified over time) have had several attendees from the same Company attend or request the course to be run in their own Company because of the savings in having multiple attendees training on-site.

Our course ratings have never been below 90% satisfaction and very often are closer to 100%.

Click here to see the current training courses available or email us here.

PharSafer® Tweets

Adverse events are overlooked and under-reported. As we head towards the turn of a decade and, almost certainly, a… t.co/yVkzPuJnjQ

Read on Twitter...

Information accessibility to risks associated with drugs is one of the major obstacles preventing patients from rec… t.co/L2feFXDN1X

Read on Twitter...

We have released our latest announcement, regarding the upcoming changes to EU Medical Device Legislation. For mo… t.co/S20M8bbiVb

Read on Twitter...